| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Sales and marketing | - | - | 41,820 | 52,059 |
| Research and development | - | - | 2,200 | 5,247 |
| Revenue | 2,855 | 7,475 | 940 | 6,580 |
| General and administrative expenses | - | - | 1,542,042 | 1,353,439 |
| Amortization | - | - | 45,438 | 4,802 |
| Selling, general and administrative expenses | 1,714,452 | 1,686,174 | - | - |
| Total operating expenses | 1,714,452 | 1,686,174 | 1,631,500 | 1,415,547 |
| Loss from operations | -1,711,597 | -1,678,699 | -1,630,560 | -1,408,967 |
| Interest income | 189 | 190 | 187 | 280 |
| Interest expense | 3,128 | 4,690 | 4,691 | 3,879 |
| Total other income (expenses) | -2,939 | -4,500 | -4,504 | -3,599 |
| Loss before provision for income taxes | -1,714,536 | -1,683,199 | -1,635,064 | -1,412,566 |
| Provision for income taxes | - | 0 | - | - |
| Net loss | -1,714,536 | -1,683,199 | -1,635,064 | -1,412,566 |
| Net loss per common share, basic | -0.98 | -0.97 | -0.97 | -0.06 |
| Net loss per common share, diluted | -0.98 | -0.97 | -0.97 | -0.06 |
| Weighted average common shares outstanding, basic | 1,757,900 | 1,739,045 | 1,686,144 | 24,442,853 |
| Weighted average common shares outstanding, fully diluted | 1,757,900 | 1,739,045 | 1,686,144 | 24,442,853 |
Cardio Diagnostics Holdings, Inc. (CDIO)
Cardio Diagnostics Holdings, Inc. (CDIO)